Comparison of healthcare resource use and cost between influenza and COVID-19 vaccine coadministration and influenza vaccination only.

IF 2.9 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Journal of Medical Economics Pub Date : 2024-01-01 Epub Date: 2024-09-20 DOI:10.1080/13696998.2024.2400852
Darshan Mehta, Tianyu Sun, Jane Wang, Aaron Situ, Yoonyoung Park
{"title":"Comparison of healthcare resource use and cost between influenza and COVID-19 vaccine coadministration and influenza vaccination only.","authors":"Darshan Mehta, Tianyu Sun, Jane Wang, Aaron Situ, Yoonyoung Park","doi":"10.1080/13696998.2024.2400852","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare healthcare resource utilization (HCRU) and all-cause medical costs among individuals aged ≥50 years who received influenza and COVID-19 vaccines on the same day and those who received influenza vaccine only.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study leveraging Optum's de-identified Clinformatics DataMart from 8/31/2021 to 7/31/2023. Individuals aged ≥50 years continuously enrolled in health plans for 1 year prior and until 7/31/2023 were included. Two cohorts were formed based on vaccination status between 8/31/2022 and 1/31/2023: co-administered influenza and COVID-19 vaccines (co-admin cohort) and influenza vaccine only (influenza cohort). Associations between vaccination status and all-cause, influenza-related, COVID-related, pneumonia-related, and cardiorespiratory-related hospitalization, outpatient or emergency room visits and all-cause medical costs were estimated by weighted generalized linear models, adjusting for confounding by stabilized inverse probability of treatment weighting.</p><p><strong>Results: </strong>613,156 (mean age: 71) and 1,340,011 (mean age: 72) individuals were included in the co-admin and influenza cohorts, respectively. After weighting, the baseline characteristics were balanced between cohorts. The co-admin cohort was at statistically significant lower risk of all-cause (RR: 0.95, 95% CI: 0.93-0.96), COVID-19-related (RR: 0.59, 95% CI: 0.56-0.63), cardiorespiratory-related (RR: 0.94, 95% CI: 0.93-0.96) and pneumonia-related (RR: 0.86, 95% CI: 0.83-0.90) hospitalization but not influenza-related hospitalizations (RR: 0.91, 95% CI: 0.81, 1.04) compared with the influenza cohort. Co-administration was associated with 3% lower all-cause medical cost (cost ratio: 0.974, 95% CI: 0.968, 0.979) during the follow-up period compared to receiving influenza vaccine only.</p><p><strong>Limitations: </strong>Limitations include the potential residual confounding bias in observational data, measurement errors from claims data, and that the cohort was followed for a single season.</p><p><strong>Conclusion: </strong>Receiving co-administered COVID-19 and influenza vaccines versus only receiving influenza vaccination reduced the risk of HCRU, especially COVID-19-related hospitalization and all-cause medical costs. Increasing vaccine coverage, particularly for COVID-19, might have public health and economic benefits.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"1190-1196"},"PeriodicalIF":2.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2024.2400852","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To compare healthcare resource utilization (HCRU) and all-cause medical costs among individuals aged ≥50 years who received influenza and COVID-19 vaccines on the same day and those who received influenza vaccine only.

Methods: We conducted a retrospective cohort study leveraging Optum's de-identified Clinformatics DataMart from 8/31/2021 to 7/31/2023. Individuals aged ≥50 years continuously enrolled in health plans for 1 year prior and until 7/31/2023 were included. Two cohorts were formed based on vaccination status between 8/31/2022 and 1/31/2023: co-administered influenza and COVID-19 vaccines (co-admin cohort) and influenza vaccine only (influenza cohort). Associations between vaccination status and all-cause, influenza-related, COVID-related, pneumonia-related, and cardiorespiratory-related hospitalization, outpatient or emergency room visits and all-cause medical costs were estimated by weighted generalized linear models, adjusting for confounding by stabilized inverse probability of treatment weighting.

Results: 613,156 (mean age: 71) and 1,340,011 (mean age: 72) individuals were included in the co-admin and influenza cohorts, respectively. After weighting, the baseline characteristics were balanced between cohorts. The co-admin cohort was at statistically significant lower risk of all-cause (RR: 0.95, 95% CI: 0.93-0.96), COVID-19-related (RR: 0.59, 95% CI: 0.56-0.63), cardiorespiratory-related (RR: 0.94, 95% CI: 0.93-0.96) and pneumonia-related (RR: 0.86, 95% CI: 0.83-0.90) hospitalization but not influenza-related hospitalizations (RR: 0.91, 95% CI: 0.81, 1.04) compared with the influenza cohort. Co-administration was associated with 3% lower all-cause medical cost (cost ratio: 0.974, 95% CI: 0.968, 0.979) during the follow-up period compared to receiving influenza vaccine only.

Limitations: Limitations include the potential residual confounding bias in observational data, measurement errors from claims data, and that the cohort was followed for a single season.

Conclusion: Receiving co-administered COVID-19 and influenza vaccines versus only receiving influenza vaccination reduced the risk of HCRU, especially COVID-19-related hospitalization and all-cause medical costs. Increasing vaccine coverage, particularly for COVID-19, might have public health and economic benefits.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
联合接种流感疫苗和 COVID-19 疫苗与仅接种流感疫苗在医疗资源使用和成本方面的比较。
目的比较在同一天接种流感疫苗和 COVID-19 疫苗的 50 岁以上人群与仅接种流感疫苗的人群的医疗资源利用率 (HCRU) 和全因医疗成本:我们在 2021 年 8 月 31 日至 2023 年 7 月 31 日期间利用 Optum 的去标识 Clinformatics DataMart 进行了一项回顾性队列研究。研究对象包括在 2023 年 7 月 31 日之前的 1 年中连续加入健康计划的年龄≥50 岁的个人。根据 2022 年 8 月 31 日至 2023 年 1 月 31 日期间的疫苗接种情况分为两个队列:联合接种流感疫苗和 COVID-19 疫苗队列(联合接种队列)和仅接种流感疫苗队列(流感队列)。疫苗接种情况与全因、流感相关、COVID 相关、肺炎相关和心肺相关住院、门诊或急诊就诊以及全因医疗费用之间的关系通过加权广义线性模型进行估算,并通过稳定的逆治疗概率加权调整混杂因素:613,156人(平均年龄:71岁)和1,340,011人(平均年龄:72岁)分别被纳入联合用药队列和流感队列。经过加权后,两组人群的基线特征趋于平衡。联合用药队列的全因风险(RR:0.95,95% CI:0.93-0.96)、COVID-19 相关风险(RR:0.59,95% CI:0.56-0.63)、心肺功能相关风险(RR:0.94,95% CI:0.93-0.96)和肺炎相关住院(RR:0.86,95% CI:0.83-0.90),但与流感队列相比,流感相关住院(RR:0.91,95% CI:0.81,1.04)不相关。与仅接种流感疫苗相比,联合接种可使随访期间的全因医疗费用降低3%(费用比:0.974,95% CI:0.968,0.979):局限性包括观察数据中可能存在的残余混杂偏差、索赔数据的测量误差以及队列的随访时间仅为一个季节:联合接种 COVID-19 和流感疫苗与只接种流感疫苗相比,可降低 HCRU 风险,尤其是与 COVID-19 相关的住院和全因医疗费用。提高疫苗覆盖率,尤其是 COVID-19 疫苗的覆盖率,可能会带来公共卫生和经济效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Medical Economics
Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL
CiteScore
4.50
自引率
4.20%
发文量
122
期刊介绍: Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience
期刊最新文献
The burden of venous thromboembolism in ten countries: a cost-of-illness Markov model on surgical and ICU patients. The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany. The indirect costs of five cancers in Egypt: years of life lost and productivity costs. Healthcare resource utilization and costs among treatment-naïve people with HIV in state Medicaids: analysis of multi-tablet vs. single-tablet antiretroviral regimen initiators with and without concurrent mental health disorders. Cost-utility analysis of newborn screening for spinal muscular atrophy in Japan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1